BNET Industries
Market Cap:$359.6K
- Public
Dow Jones Description
We were incorporated under the laws of the state of Delaware on October 6, 1998 under the name of San Jose International, Inc. On August 19, 2004, we changed the name of our company to Gammacan International, Inc. in the State of Delaware. During our first quarter ended December 31, 2003, we identified a promising business prospect focused on the seismic acquisition business located in Western Canada and agreed in principal to acquire all of the shares of two Alberta based companies. However, on April 20, 2004, we decided to terminate our efforts to pursue this proposed acquisition, because it appeared we would not be successful in obtaining the necessary financing on a timely basis. Pursuant to an agreement for purchase and sale of intellectual property between our subsidiary, Gammacan, Ltd., and ARP Biomed, Ltd. ("ARP), we completed the purchase and sale of the intellectual property on August 17, 2004. As a result, we now own all of ARP's rights and interests in the intellectual property assets (the "Intellectual Property") consisting of intravenous immunoglobulin ("IVIG") research and development, patents and other intellectual property, which appears to hold promising potential for the clinical treatment for various cancer types.
President
Steven KatzContact Information
Kiryat Ono Mall, Azorim Center A
39 Jerusalem St.
Kiryat Ono 55423
972-3-7382616
Peer Companies
NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414
News & Analysis
Filter by
gammacan international inc. - All News and Analysis
Speak with other shareholders about: (OTCBB: RGBL), (OTCBB: GCAN), (OTCBB: IYXI) and (NASDAQ: XOMA).
M2 PRESSWIRE-1 March 2007-Stockwire.com: Speak with other shareholders about: (OTCBB: RGBL), (OTCBB: GCAN), (OTCBB: IYXI) and (NASDAQ: XOMA).C1994-2007 M2 COMMUNICATIONS LTD RDATE:01032007 AUSTIN - A very interesting indicator to look for is where the money is flowing into. We have a...
GammaCan Signs $6.5 Million Private Placement with Institutional Investors
KIRYAT ONO, Israel & NEW YORK -- GammaCan International, Inc. ("GammaCan" or "the Company") (OTCBB: GCAN), a developer of novel immunotherapies to treat cancer, announced today the completion of a $6.5 million private placement with a group of investors lead by T.R. Winston & Company, LLC. The Company issued 16,250,000...
Alerts for Thursday, August 31, 2006 - Featuring Trend Mining, Franchise Capital, GammaCan International, Horizon Offshore, and More.
M2 PRESSWIRE-31 August 2006-TalkingStocks.com: Alerts for Thursday, August 31, 2006 - Featuring Trend Mining, Franchise Capital, GammaCan International, Horizon Offshore, and MoreC1994-2006 M2 COMMUNICATIONS LTD RDATE:31082006 Dallas, Texas - Talking Stocks Pre-Market Updates for Thursday include Trend Mining Company (OTCBB:...
Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 Presenter Profiles
MONTE CARLO, Monaco -- Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 takes place May 15-16 in Monte Carlo. For in-depth information about the event visit http://www.rodmanandrenshaw.com/Conferences.asp?CID=conf9. Below are profiles from Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 presenters; breaking news releases are available at...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Steven Katz | President |
| David DeMedio | Director |
Steven Katz joined the Board of Directors in May 1999. He is President of Steven Katz & Associates, Inc., a management consulting firm specializing in strategic planning and corporate development for technology and service-based companies in the health care, environmental, telecommunications and Internet markets. Mr. Katz's prior experience includes five years with PriceWaterhouse & Co. in audit, tax and management advisory services; two years of corporate planning with Revlon, Inc.; five years with National Patent Development Corporation (NPDC) in strategic planning, merger and acquisition, technology in-licensing and out-licensing, and corporate turnaround experience as President of three NPDC subsidiaries; and two years as a Vice President and General Manager of a non-banking division of Citicorp, N.A. Mr. Katz is also a Director of Health Systems Solutions Inc. and NaturalNano, Inc., each publicly traded companies. Mr. Katz is also President and Chairman of the Board of Gammacan International, Inc., a publicly traded company.
| Organization | Position | Status |
|---|---|---|
| Gammacan International, Inc. | President | Current |
| Gammacan Ltd. | Chairman of the Board of Directors and President | Current |
| Infinity Capital Group, Inc. | Senior Vice President Business Development, Director | Current |
| Nuvotec | Current | |
| Gammacan International, Inc. | Chairman of the Board | Current |
| USA Technologies Inc | Chairman | Current |
| Naturalnano, Inc. | Chairman | Current |
| Infinity Capital Group, Inc. | Board of Directors | Current |
| Health Systems Solutions, Inc. | Director | Current |
| Biophan Technologies, Inc. | Director | Current |
| Vivid Learning Systems, Inc. | Director | Current |
| Nanoscience Technologies, Inc. | Director | Current |
| Gammacan Ltd. | Board of Directors | Current |
| Senesco Technologies Inc. | President | Former |
| National Patent Development Corp | President | Former |
| Senesco Technologies Inc. | Chief Operating Officer | Former |
| S.K.Y. Polymers, Inc. | Executive Vice President | Former |
| Citicorp | Vice President | Former |
| Citicorp | General Manager | Former |
| S.K.Y. Polymers, Inc. | Co-Founder | Former |
| Price Waterhouse & Co. | senior accountant | Former |
| Revlon, Inc. | Former | |
| Senesco Technologies Inc. | Director | Former |
| USA Technologies Inc | Director | Current |
| City College of New York | B.B.A. in June | Former |
| City College of New York | degree in Business Administration and Accounting | Former |
| Biophan Technologies, Inc. | member | Former |
David M. DeMedio joined USA Technologies on a full-time basis in March 1999 as Controller. In the Summer of 2001, Mr. DeMedio was promoted to Director of Financial Services where he was responsible for the sales and financial data reporting to customers, the Company's turnkey banking services and maintaining and developing relationships with credit card processors and card associations. In July 2003, Mr. DeMedio served as interim Chief Financial Officer through April, 2004. From April, 2004 until April 12, 2005, Mr. DeMedio served as Vice President - Financial & Data Services. On April 12, 2005, he was appointed as the Company's Chief Financial Officer. From 1996 to March 1999, prior to joining the Company, Mr. DeMedio had been employed by Elko, Fischer, Cunnane and Associates, LLC as a supervisor in its accounting and auditing and consulting practice. Prior thereto, Mr. DeMedio held various accounting positions with Intelligent Electronics, Inc., a multi-billion reseller of computer hardware and configuration services. Mr. DeMedio graduated with a Bachelor of Science in Business Administration from Shippensburg University and is a Certified Public Accountant. Mr. DeMedio is a Director of Gammacan International, Inc., a publicly traded company.
| Organization | Position | Status |
|---|---|---|
| USA Technologies Inc | Cfo | Current |
| Corp USA, Inc. | Controller and Director | Current |
| USA Technologies Inc | Controller | Current |
| Gammacan International, Inc. | Director | Current |
| Gammacan Ltd. | Board of Directors | Current |
| USA Technologies Inc | Vice President, Finance & Data Services | Former |
| Intelligent Electronics | Former | |
| Shippensburg University | Bachelor of Science In Business Administration | Former |
| Volume | 50,000 |
| Shares Outstanding | 44.9M |
| Market Cap | 359.6K |
| Year High | 0.040 |
| Year Low | 0.0021 |
| Earnings Per Share | -0.10 |
| P/E Ratio | N/A |
| Dividend | 0.00 |
| Yield | 0.00 |
Industry Transcripts by Seeking Alpha
-
XOMA Ltd. Q3 2009 Earnings Call Transcript
on Nov 09, 2009about XOMA
-
Halozyme Therapeutics, Inc. Q3 2009 Earnings Call Transcript
on Nov 06, 2009about HALO
-
Momenta Pharmaceuticals, Inc. Q3 2009 Earnings Call Transcript
on Nov 06, 2009about MNTA
-
Emergent BioSolutions Inc. Q3 2009 Earnings Call Transcript
on Nov 05, 2009about EBS
-
Targacept, Inc. Q3 2009 Earnings Call Transcript
on Nov 05, 2009about TRGT
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Best Selling Drugs Will Soon be Biologics, But Not Owned by Biotechs 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes


